The UMCCC High-Throughput Screening (HTS) Core is a new core which offers center investigators the opportunity to translate hypothesis-driven research into clinically relevant discoveries. In general these efforts focus on dissecting the cellular and molecular mechanisms of cancer through the application of chemical genomics strategies. The UMCCC-HTS Core provides access to compound libraries, screening services, expert consultation, and information sharing for researchers interested in HTS of small molecules, natural product extracts and/or siRNA genomes. The biological and chemical collections at the core are also available for cell profile screening, targeted biology approaches and structure-based molecular modeling. The Core also provides screening to several regional universities and has ongoing collaborations with a number of outside non-profit research Institutions. The core staff assist researchers with assay development, provide training in general HTS techniques, supervise screening campaigns on biomedical targets, manage assay results In a secure relational database and provide advice on counter and secondary screening. Within the HTS Core, medicinal chemistry resources are available for consultation on appropriate follow-up compounds and structure-activity relationship (SAR) analysis. The UMCCC-HTS Core also has an alliance with the Center for Computational Medicine end Bioinformatics (CCMB) to use bioinformatics tools (ConceptGen) for analysis of siRNA HTS results (Sautor et al., 2010). The Core can fully support UMCCC objectives to Identify small molecule probes, potential therapeutic leads and genomic pathways Implicated In malignant diseases, Cancer biology (and relevant genetic models) has been investigated using biochemical and cell-based assays and many of these are amenable to HTS technologies such as flow cytometry, high-content analysis, spectrophotometric detection and transcriptional reporter systems (Collins and Workman, 2006). siRNA HTS, using whole genome or selected subsets of genes, provides pathway analysis and mechanism-based Interrogation of specific genes responsible for human cancer processes. The core and its database of screening results can be used for Individual target-based drug discovery or to Investigate specific chemotypes that affect related targets. Thus, the UMCCC-HTS core is well-positioned to facilitate the discovery of chemical probes for identification and interrogation of cancer targets at the molecular level.

Public Health Relevance

This program funding for the HTS Core will provide University of Michigan scientists with the resources to rapidly test hundreds of thousands of chemicals and thousands of genes for their effects on cells, proteins and enzymes. These studies will provide a first step toward Identifying new drugs to treat cancer and the relevant pathways Involved cancer pathologies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90
Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396

Showing the most recent 10 out of 1493 publications